摘要
目的 肝动脉化疗栓塞（TACE）联合索拉非尼治疗中晚期肝癌的有效性探讨。方法 回顾性分析67例肝癌病患，其中对照组33例仅行TACE治疗，实验组34例加用索拉非尼，对比两组患者的用药有效率及不良反应。结果 在临床疗效方面实验组优于对照组（P<0.05）；两组不良反应包括手足综合征、腹泻、皮疹、高血压和肝功能异常等，差别无统计分析意义（P>0.05）。结论 索拉非尼联合TACE治疗中晚期肝癌有效、安全，临床应用价值值得肯定。
关键词： 肝细胞癌；栓塞；索拉非尼
Abstract
Objective : Evaluation of the efficacy of TACE combined sorafenib on advanced hepatocellular carcinoma. Methods : Retrospective analysis 67 patients with liver cancer, the control group (33 cases) only received TACE treatment, in the experimental group, 34 patients were given TACE and sorafenib, the effective rate and adverse reactions of the two groups were compared. Results : The experimental group is superior to the Control Group in Clinical Curative Effect (P<0.05). The two groups of adverse reactions included Hand-foot syndrome, diarrhea, skin rash, hypertension and liver dysfunction, the difference was not statistically significant (P>0.05). Conclusion : sorafenib combined with TACE in the treatment of advanced liver cancer are effective and safe.And clinical value is worthy of affirmation.
Key words： Hepatocellular Carcinoma, Embolization, So-Rafenib
参考文献 References
[1] Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008 [J].J Hepatol,2008;48
: 20-37.
[2] Yang ZF, Poon RT. Vascular changes in hepato- cellular carcinoma[J].Anat Rec (Hoboken),2008;291
: 721-734.
[3] Zhao Y, Li HL, Bai W, et al. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib:a multicenter clini-cal study of 606 HCC patients (J).Int J Cancer,2016;139
(4)
: 928-37.
[4] 中国临床肿瘤学会. CSCO原发性肝癌诊疗指南（2018.V1)［EB/OL]http: //www. csco. org. cn/cat/147/show/8627.html..
.
[5] 中国抗癌协会肝癌专业委员会. 原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2002;9
(6)
: 324.
[6] Llovet JM,Bruix J. Molecular Targeted Therapies in Hepatocel-lular Carcinoma [J].Hepatology,2008;48
(4)
: 1312-1327.
[7] 冉恒泉,熊勇,孙昌勤. 甲磺酸阿帕替尼治疗原发性肝癌术后肺转移1例.医学前沿,2017;7
(28)
: 102-103.
[8] 张怀峰. 甲磺酸阿帕替尼治疗晚期原发性肝癌的临床疗效及安全性.智慧健康,2019;5
(04)
: 109-110.
[9] Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembo- lization?.A validation study of old and new models. Radiology,2012;262
(2)
: 708-718.
[10] Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma..JAMA,2010;303
(11)
: 1062-1069.
[11] 贺爱军,任羽,姬乐,等. 肝动脉化疗栓塞术（TACE)对原发性肝癌患者的肝功能影响及相关因素分析[J].中国实验诊断学,2016;20
(9)
: 1507-1509.
[12] 李秀荣. TSGF在原发性肝癌TACE治疗中疗效评估的应用价值[J].中国医师杂志,2017;19
(2)
: 253-256.
[13] 潘敏,余进进,黄小艳,等. 索拉非尼对人卵巢癌SK-OV-3细胞凋亡的影响[J].实用癌症杂志,2012;27
(1)
: 12-14,17.
[14] An SL, Wang LM, Rong WQ,et al. Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers [J].Chin J Cancer,2015;34
(1)
: 17.
[15] 张洪海,孙玉,郑加生. 合并门静脉癌栓肝癌的治疗现状与进展[J].临床荟萃,2015;30
(4)
: 450-456.
[16] 孙恒,韩文杰. 索拉非尼对原发性肝癌患者疗效的研究分析[J].实用癌症杂志,2014;29
(4)
: 442-444.
[17] Wilhelm SM,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].Cancer Res,2004;64
: 7099-7109.
[18] Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models [J].Caneer Chemother Pharmacol,2007;59
: 561-574.
[19] NIU L, LIU L, YANG S, et al. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies [J].Biochim Biophys Acta Rev Cancer,2017;1868
(2)
: 564-570.